EU-HTA: European Health Technology Assessment
Digital Health Applications (DiGA) & Digital Pharma
Full Market Access
Strategic Due Diligence
Market Access Strategy
Pharma & Biotech
Digital Health Provider
EU5: Commercial assessment of licensed products for the five major EU markets
Conception of the German market access for two innovatice products
Consistent brand management strengthens the clients base for health delivery
Corporate vision: long-term vision of a hospital
Digital strategy and agenda combine digitization initiatives
Discharge management of a rare disease
How effective integrated care really is
Leadership strategy and executives development
Service cost management: Limiting rising hospital spending
Strategic support and negotiation lead: AMNOG
Trial regulations: strategic support (pursuant to §137e SGB V)
Value assessment and value story for a digital solution
Written statement and oral hearing revise the initial benefit assessment
Agile & Design Thinking
Prof. Matthias P. Schönermark M.D., Ph.D.
Heike Kielhorn-Schönermark, MBA
Would you like to call us?
+49 511 64 68 14 – 0
Would you like to visit us personally?
This is how you find our office in Hannover.
Your request via contact form
* mandatory field
Yes, I agree with the
Discover the latest news from the industry, clearly and comprehensibly presented.
Confidential reimbursement amounts in Germany come with a price tag
Medical Research Act Bill
From genes to therapies - Decades of commitment to rare diseases
When bone marrow becomes the enemy
Improved orphan drug availability by the EU pharmaceutical package?
Is it realistic?
Morbus Osler (HHT)
More than just nosebleeds
Primary sclerosing cholangitis (PSC)
Liver damage and the fear of cancer due to the rare disease of the bile ducts
A ray of hope for MCT8 deficiency
Navigating the orphan drug landscape
The Implementing Act on JCA is still pending – What to do next Monday?
SKCs Top 5 Essentials
to the top